positive fin review article, page-2

yep,

resmed have the cash, ksx the new products ... asthma a huge area of medical device growth in coming years.

good to see the fin review weighing in. won;t be long before deeper pockets arrive and that's when this will pop a lot higher. has shown in the past a propensity to spike. reasonably tightly held so not a lot of loose shares floating around under double figures imv.

also trades well when the volumes are going through. will be on the radar soon enough methinks